<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="hep41480-tbl-0004" xml:lang="en" orientation="portrait" position="float">
 <label>Table 4</label>
 <caption>
  <p>Considerations for Antiviral Selection for HBV Treatment</p>
 </caption>
 <table frame="hsides" rules="groups">
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <tbody>
   <tr style="border-bottom:solid 1px #000000">
    <td align="left" colspan="2" rowspan="1">AASLD</td>
   </tr>
   <tr>
    <td align="left" style="padding-left:10%" rowspan="3" colspan="1">Guidance statements</td>
    <td align="left" rowspan="1" colspan="1">No preference between ETV or TDF regarding potential long‐term risks of renal and bone complications</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">TAF is associated with lower rates of bone and renal abnormalities than TDF</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">In cases of suspected TDF‐associated renal dysfunction and/or bone disease, TDF should be discontinued and substituted with TAF or ETV, with consideration for any previously known drug resistance</td>
   </tr>
   <tr>
    <td align="left" colspan="2" rowspan="1">EASL</td>
   </tr>
   <tr>
    <td align="left" style="padding-left:10%" rowspan="11" colspan="1">Indications for selection of ETV or TAF over TDF</td>
    <td align="left" rowspan="1" colspan="1">
     <bold>Age</bold>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">&gt; 60 years</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">
     <bold>Bone disease</bold>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Chronic use of medications that worsen bone density (including steroids)</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">History of fragility fractures</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Osteoporosis</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">
     <bold>Renal dysfunction</bold>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">eGFR &lt;60 mL/min/1.73 m
     <sup>2</sup>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Albuminuria &gt;30 mg/24 hours or urinalysis with moderate qualitative proteinuria</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Hypophosphatemia (&lt;2.5 mg/dL)</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">On hemodialysis</td>
   </tr>
   <tr>
    <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Recommendation statements</td>
    <td align="left" rowspan="1" colspan="1">Patients on TDF at risk of development and/or with underlying renal or bone disease should be considered for a switch to ETV or TAF, depending on previous treatments</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot id="hep41480-ntgp-0005">
  <fn id="hep41480-note-0013">
   <p>Abbreviations: eGFR, estimated glomerular filtration rate; ETV, entecavir; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.</p>
  </fn>
 </table-wrap-foot>
 <permissions>
  <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
 </permissions>
</table-wrap>
